BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 11230791)

  • 1. Simvastatin treatment on postprandial hypertriglyceridemia in type 2 diabetes mellitus patients with combined hyperlipidemia.
    Sheu WH; Jeng CY; Lee WJ; Lin SY; Pei D; Chen YT
    Metabolism; 2001 Mar; 50(3):355-9. PubMed ID: 11230791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
    Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment.
    Ansell BJ; Navab M; Hama S; Kamranpour N; Fonarow G; Hough G; Rahmani S; Mottahedeh R; Dave R; Reddy ST; Fogelman AM
    Circulation; 2003 Dec; 108(22):2751-6. PubMed ID: 14638544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
    Grundy SM; Vega GL; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2009 Aug; 104(4):548-53. PubMed ID: 19660610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-lowering therapy does not affect the postprandial drop in high density lipoprotein-cholesterol (HDL-c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial.
    Hajer GR; Dallinga-Thie GM; van Vark-van der Zee LC; Olijhoek JK; Visseren FL
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):870-7. PubMed ID: 18394022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C.
    Miller M; Dobs A; Yuan Z; Battisti WP; Borisute H; Palmisano J
    Curr Med Res Opin; 2004 Jul; 20(7):1087-94. PubMed ID: 15265253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia.
    Vigna GB; Donega P; Passaro A; Zanca R; Cattin L; Fonda M; Pauciullo P; Marotta G; Fellin R; Gasparrini S; Piliego T
    Nutr Metab Cardiovasc Dis; 1999 Oct; 9(5):234-43. PubMed ID: 10656170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
    Udawat H; Goyal RK
    Indian Heart J; 2001; 53(2):172-6. PubMed ID: 11428472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events.
    Michelena HI; Osorio LA; Citkowitz E
    Int J Cardiol; 2005 May; 101(1):111-4. PubMed ID: 15860392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study.
    Akçiçek F; Ok E; Duman S; Kürsad S; Unsal A; Alev M; Atabay G; Basçi A
    Adv Perit Dial; 1996; 12():261-5. PubMed ID: 8865916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.
    Durrington PN; Tuomilehto J; Hamann A; Kallend D; Smith K
    Diabetes Res Clin Pract; 2004 May; 64(2):137-51. PubMed ID: 15063607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).
    Grundy SM; Vega GL; Yuan Z; Battisti WP; Brady WE; Palmisano J
    Am J Cardiol; 2005 Feb; 95(4):462-8. PubMed ID: 15695129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
    Maki KC; McKenney JM; Reeves MS; Lubin BC; Dicklin MR
    Am J Cardiol; 2008 Aug; 102(4):429-33. PubMed ID: 18678300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline achievement of lipid goals and usage of lipid medications in patients with diabetes mellitus (from the Veterans Affairs Diabetes Trial).
    Meyers CD; McCarren M; Wong ND; Abraira C; Duckworth WC; Kashyap ML;
    Am J Cardiol; 2006 Jul; 98(1):63-5. PubMed ID: 16784922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT; Anderson JL; Pearson RR; Jensen JR; Horne BD; Lavasani F; Yannicelli HD; Muhlestein JB
    Am J Cardiol; 2008 Feb; 101(4):486-9. PubMed ID: 18312763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of simvastatin on HDL cholesterol in hyperlipidemic patients. Evidence of a relationship with the changes in serum triglyceride level.
    Branchi A; Rovellini A; Fiorenza AM; Maraffi F; Gandini R; Sommariva D
    Int J Clin Pharmacol Ther; 1996 Sep; 34(9):384-9. PubMed ID: 8880287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
    Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A.
    Superko HR; Berneis KK; Williams PT; Rizzo M; Wood PD
    Am J Cardiol; 2005 Nov; 96(9):1266-72. PubMed ID: 16253595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.
    Iovine C; Lilli S; Gentile A; Patti L; Di Marino L; Cipriano P; Riccardi G; Rivellese AA
    Eur J Clin Invest; 2006 Aug; 36(8):560-5. PubMed ID: 16893378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.